Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0U5CS
|
|||
| Former ID |
DCL000158
|
|||
| Drug Name |
LY354740
|
|||
| Synonyms |
Eglumetad; Eglumegad; 176199-48-7; (1S,2S,5R,6S)-2-aminobicyclo[310]hexane-2,6-dicarboxylic acid; Eglumegad [INN]; UNII-ONU5A67T2S; LY-354740; LY 354740; ONU5A67T2S; CHEMBL8759; Eglumegad (INN); (1S,2S,5R,6S)-2-Aminobicyclo(310)hexane-2,6-dicarboxylic acid; (1R,4S,5S,6S)-4-aminobicyclo[310]hexane-4,6-dicarboxylic acid; (1S,2S,5R,6S)-2-Amino-bicyclo[310]hexane-2,6-dicarboxylic acid; [3H]Eglumegad; LY366563; Eglumetad [USAN:INN]; (+)-2-Aminobicyclo(310)hexane-2,6-dicarboxylic acid; 40F; PubChem18158; Eglumegad; Eglumegad [USAN]; Eglumegad hydrate; Eglumetad hydrate; LY 314582; LY 366563; LY314582; Eglumegad (USAN); LY-314582; LY-354740 monohydrate; LY-366563; Eglumetad (INN/USAN); (1R,4S,5S,6S)-4-aminobicyclo[310]hexane-4,6-dicarboxylic acid hydrate; (1S,2S,5R,6S)-2-Aminobicyclo(310)hexane-2,6-dicarboxylic acid monohydrate; 2-Aminobicyclo(310)hexane-2,6-dicarboxylic acid; 4-aminobicyclo[310]hexane-4,6-dicarboxylic acid; [3H]eglumegad
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Anxiety disorder [ICD-11: 6B00-6B0Z; ICD-10: R45.0] | Discontinued in Phase 2 | [1], [2] | |
| Company |
Eli Lilly
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C8H11NO4
|
|||
| Canonical SMILES |
C1CC(C2C1C2C(=O)O)(C(=O)O)N
|
|||
| InChI |
1S/C8H11NO4/c9-8(7(12)13)2-1-3-4(5(3)8)6(10)11/h3-5H,1-2,9H2,(H,10,11)(H,12,13)/t3-,4-,5-,8-/m0/s1
|
|||
| InChIKey |
VTAARTQTOOYTES-RGDLXGNYSA-N
|
|||
| CAS Number |
CAS 176199-48-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7979829, 9371121, 14748421, 15171407, 30417292, 49893662, 57399664, 76123878, 96025591, 99374044, 103066678, 103078431, 103167812, 103952580, 113453194, 117518357, 126681491, 129522756, 134222157, 134338837, 134342627, 135188014, 135650554, 135651173, 137008428, 141864460, 143494992, 152039494, 152165111, 152238648, 162221554, 163304092, 163346685, 170485584, 198977294, 202548619, 204373912, 223661924, 223886305, 225144924, 226393133, 226797883, 249727659, 252213797
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Metabotropic glutamate receptor 2 (mGluR2) | Target Info | Agonist | [3] |
| Metabotropic glutamate receptor 3 (mGluR3) | Target Info | Agonist | [4], [5], [6] | |
| KEGG Pathway | Neuroactive ligand-receptor interaction | |||
| Glutamatergic synapse | ||||
| Cocaine addiction | ||||
| Panther Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Ionotropic glutamate receptor pathway | ||||
| Metabotropic glutamate receptor group II pathway | ||||
| Reactome | G alpha (i) signalling events | |||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | ||||
| WikiPathways | GPCRs, Class C Metabotropic glutamate, pheromone | |||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1393). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800008428) | |||
| REF 3 | Characterization of [(3)H]-LY354740 binding to rat mGlu2 and mGlu3 receptors expressed in CHO cells using semliki forest virus vectors. Neuropharmacology. 2000 Jul 24;39(10):1700-6. | |||
| REF 4 | Mutagenesis and molecular modeling of the orthosteric binding site of the mGlu2 receptor determining interactions of the group II receptor antagonist (3)H-HYDIA. ChemMedChem. 2009 Jul;4(7):1086-94. | |||
| REF 5 | Effects of a metabotropic glutamate receptor group II agonist LY354740 in animal models of positive schizophrenia symptoms and cognition. Behav Pharmacol. 2009 Feb;20(1):56-66. | |||
| REF 6 | Modulation of group II metabotropic glutamate receptor (mGlu2) elicits common changes in rat and mice sleep-wake architecture. Eur J Pharmacol. 2009 Jan 28;603(1-3):62-72. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.